Patents Assigned to Cipla Limited
  • Bezafibrate for the treatment of cancer
    Patent number: 10857113
    Abstract: Methods of treating renal cancer, including renal cell carcinoma, using bezafibrate are disclosed herein. Bezafibrate can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: December 8, 2020
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • RIFAXIMIN
    Publication number: 20200368212
    Abstract: Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.
    Type: Application
    Filed: February 28, 2020
    Publication date: November 26, 2020
    Applicant: CIPLA Limited
    Inventors: Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan, Manjinder Singh Phull, Muruti Ghagare
  • Methods for the treatment of hepatitis C
    Patent number: 10765644
    Abstract: The present invention relates to method of treatment of hepatitis C using hexestrol or a derivative thereof. The methods of the present invention can be used in patients with hepatitis C administering hexestrol or a derivative thereof in combination with one or more anti-hepatitis C drugs.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: September 8, 2020
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi
  • Method of treating hypertension
    Patent number: 10709715
    Abstract: Disclosed herein are methods of treating pulmonary hypertension, including pulmonary arterial hypertension, by administering to a patient in need thereof an effective amount of temozolomide, optionally in conjunction with one or more additional therapeutic agents. Compositions and kits including temozolomide for use in treating pulmonary hypertension, including pulmonary arterial hypertension, are also disclosed.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: July 14, 2020
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • Rifaximin
    Patent number: 10702505
    Abstract: Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: July 7, 2020
    Assignee: CIPLA Limited
    Inventors: Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan, Manjinder Singh Phull, Muruti Ghagare
  • RIFAXIMIN COMPLEXES
    Publication number: 20200147225
    Abstract: There is provided a complex comprising rifaximin and a complexing agent, wherein the complexing agent is a polyvinyl pyrrolidone (PVP) or a cyclodextrin. There is also provided a process for preparing the complex, a pharmaceutical composition including the complex and therapeutic uses of the complex.
    Type: Application
    Filed: June 13, 2019
    Publication date: May 14, 2020
    Applicant: Cipla Limited
    Inventors: Maruti Ganpati Ghagare, Sunilkumar Parasnath Saroj, Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan
  • PHARMACEUTICAL COMPOSITIONS COMPRISING RIFAXIMIN
    Publication number: 20200046688
    Abstract: A pharmaceutical composition is provided for the treatment of systemic infections as well as colonic diseases. The composition comprises a therapeutically effective amount of rifaximin and a therapeutically effective amount of at least one alkaloid or derivative thereof. Methods and kits are also provided.
    Type: Application
    Filed: October 13, 2017
    Publication date: February 13, 2020
    Applicant: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • Stabilized cabazitaxel formulations
    Patent number: 10500185
    Abstract: Disclosed herein are improved formulations for the cabazitaxel. The formulations exhibit increased storage stability relative to other formulations, and are simpler for health care providers to prepare and administer to patients.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: December 10, 2019
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Sarabjit Singh, Ravichandra Bhadravathi Vedamurthy, Anirban Mallik Thakur, Dhiraj Abhyankar
  • Stable carfilzomib formulations
    Patent number: 10493079
    Abstract: Disclosed herein are stabilized formulations of carfilzomib. The formulations exhibit increased storage stability relative to other formulations, and are simpler for health care providers to prepare and administer to patients.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: December 3, 2019
    Assignee: Cipla Limited
    Inventors: Harshad Kishore Shete, Pankaj Omprakash Pathak, Sarabjit Singh, Geena Malhotra
  • Thienopyridine derivative for the treatment of hepatitis C infections
    Patent number: 10471048
    Abstract: The present invention relates to methods of treatment of hepatitis C using prasugrel. The methods of the present invention can be used in patients with hepatitis C administering prasugrel in combination with one or more anti-hepatitis C drugs.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: November 12, 2019
    Assignee: Cipla Limited
    Inventors: Karl Roberts, Geena Malhotra, Dhiraj Abhyankar, Kalpana Joshi, Jeevan Ghosalkar
  • Pharmaceutical antiretroviral composition
    Patent number: 10420727
    Abstract: A pharmaceutical composition comprises at least one integrase inhibitor or its salt, solvate, complex, hydrate, isomer, ester, tautomer, anhydrate, enantiomer, polymorph or prodrug and at least one antiretroviral or anti-HIV agent or its salt, solvate, complex, hydrate, isomer, ester, tautomer, anhydrate, enantiomer, polymorph or prodrug.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: September 24, 2019
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Shrinivas Purandare
  • Ketorolac for the treatment of cancer
    Patent number: 10391080
    Abstract: Methods of treating cancer, including PAR-4 implicated cancers or renal cell carcinoma, using ketorolac are disclosed herein. Ketorolac can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: August 27, 2019
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • Rifaximin complexes
    Patent number: 10328153
    Abstract: There is provided a complex comprising rifaximin and a complexing agent, wherein the complexing agent is a polyvinyl pyrrolidone (PVP) or a cyclodextrin. There is also provided a process for preparing the complex, a pharmaceutical composition including the complex and therapeutic uses of the complex.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: June 25, 2019
    Assignee: Cipla Limited
    Inventors: Maruti Ganpati Ghagare, Sunilkumar Parasnath Saroj, Dharmaraj Ramachandra Rao, Rajendra Narayanrao Kankan
  • Stabilized liquid fosaprepitant formulations
    Patent number: 10307432
    Abstract: The present invention relates to stable pharmaceutical compositions of fosaprepitant or a salt thereof in the form of ready-to-use or ready-to-dilute compositions suitable for parenteral administration.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: June 4, 2019
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Sarabjit Singh, Abhijit Jadhav
  • Polymorphic form X of nilotinib dihydrochloride hydrate
    Patent number: 10301282
    Abstract: The present invention relates to a novel polymorph of nilotinib hydrochloride (Form X), to processes for its preparation, to pharmaceutical compositions containing the same and to its use in medicine.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: May 28, 2019
    Assignee: Cipla Limited
    Inventors: Dharmaraj Ramachandra Rao, Geena Malhotra, Srinivas Laxminarayan Pathi, Venugopalarao Chinimilli, Manish Gopaldas Gangrade
  • Polymorphic forms of methyl((1S)-1-(((2S)-2-(5-(4?-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate and salts thereof
    Patent number: 10300044
    Abstract: Amorphous methyl((1S)-1-(((2S)-2-(5-(4?-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl) carbamate free base, amorphous methyl((1S)-1-(((2S)-2-(5-(4?-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl) carbamate dihydrochloride, methods of making them, and pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: May 28, 2019
    Assignee: Cipla Limited
    Inventors: Dharmaraj Ramachandra Rao, Geena Malhotra, Manjinder Singh Phull, Shashirekha Kanathala, Manish Gopaldas Gangrade
  • Process for the preparation of apremilast
    Patent number: 10287248
    Abstract: The present invention relates to novel processes for the preparation of apremilast of formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: May 14, 2019
    Assignee: CIPLA LIMITED
    Inventors: Dharmaraj Ramachandra Rao, Geena Malhotra, Srinivas Laxminarayan Pathi, Ravikumar Puppala, Suryanarayana Durga Yarra
  • Mesalamine for the treatment of cancer
    Patent number: 10220072
    Abstract: Methods of treating renal cancer, including renal cell carcinoma, using mesalamine are disclosed herein. Mesalamine can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: March 5, 2019
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof
    Patent number: 10208058
    Abstract: The present invention discloses a novel process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts thereof and to novel intermediates which are produced during the course of carrying out the novel process.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: February 19, 2019
    Assignee: CIPLA LIMITED
    Inventors: Dharmaraj Ramachandra Rao, Geena Malhotra, Venkata Srinivas Pullela, Vinod Parameshwaran Acharya, Nagarjuna Reddy Vantadou
  • Stabilized cabazitaxel formulations
    Patent number: 10188626
    Abstract: Disclosed herein are improved formulations for the cabazitaxel. The formulations exhibit increased storage stability relative to other formulations, and are simpler for health care providers to prepare and administer to patients.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: January 29, 2019
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Sarabjit Singh, Ravichandra Bhadravathi Vedamurthy, Anirban Mallik Thakur, Dhiraj Abhyankar